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Background: Knowledge of the oncogenic signaling pathways of T-cell acute lymphoblastic leukemia (T-ALL)
remains limited. Constitutive aberrant activation of the nuclear factor kappa B (NF-κB) signaling pathway has been
detected in various lymphoid malignancies and plays a key role in the development of these carcinomas. The zinc
finger-containing protein, A20, is a central regulator of multiple NF-κB-activating signaling cascades. A20 is
frequently inactivated by deletions and/or mutations in several B-and T-cell lymphoma subtypes. However, few
A20 mutations and polymorphisms have been reported in T-ALL. Thus, it is of interest to analyze the expression
characteristics of A20 and its regulating factors, including upstream regulators and the CBM complex, which
includes CARMA1, BCL10, and MALT1.
Methods: The expression levels of CARMA1, BCL10, MALT1, A20, and NF-κB were detected in peripheral blood
mononuclear cells (PBMCs) from 21 patients with newly diagnosed T-ALL using real-time PCR, and correlations
between the aberrant expression of these genes in T-ALL was analyzed. Sixteen healthy individuals, including 10
males and 6 females, served as controls.
Results: Significantly lower A20 expression was found in T-ALL patients (median: 4.853) compared with healthy
individuals (median: 8.748; P = 0.017), and significantly increased expression levels of CARMA1 (median: 2.916;
P = 0.034), BCL10 (median: 0.285; P = 0.033), and MALT1 (median: 1.201; P = 0.010) were found in T-ALL compared
with the healthy individuals (median: 1.379, 0.169, and 0.677, respectively). In contrast, overexpression of NF-κB (median:
0.714) was found in T-ALL compared with healthy individuals (median: 0.335; P = 0.001). A negative correlation
between the MALT1 and A20 expression levels and a positive correlation between CARMA1 and BCL10 were found
in T-ALL and healthy individuals. However, no negative correlation was found between A20 and NF-κB and the
MALT1 and NF-κB expression level in the T-ALL group.
Conclusions: We characterized the expression of the CARMA-BCL10-MALT1-A20-NF-κB pathway genes in T-ALL.
Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of
A20, which enhances NF-κB signaling and may be related to T-ALL pathogenesis.
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T-cell acute lymphoblastic leukemia (T-ALL), which ac-
counts for 15% of all newly diagnosed ALL cases in chil-
dren and 20 to 25% of ALL cases in adults, results from
clonal malignant T-cell proliferation, is an aggressive
malignancy that does not respond well to chemotherapy,
and has poorer prognosis than its B-cell counterpart
[1-3]. The cellular biology and pathogenesis of T-ALL
are relatively complex, and these might be related to the
different original malignant T-cell clone, e.g., T-ALL cases
with two malignant T-cell clones or a mono-malignant
T-cell clone have different gene expression patterns [4-6].
It has also been reported that the acute and lymphoma
subtypes of adult T-cell leukemia/lymphomas are genomi-
cally distinct; thus, they may develop tumors via different
genetic pathways as suggested by comparative analysis of
their genomic profiles [7]. Complex acquired genetic aber-
rations include chromosomal translocations, and gene re-
arrangements and mutations, resulting in the abnormal
expression of oncogenes such as Notch1, TAL1 (T-cell
acute lymphoblastic leukemia 1), and BCL11B (B-cell
chronic lymphocytic leukemia/lymphoma 11B), which
may be associated with advanced disease and resistance
to treatment [8-14]. In contrast, abnormal T-cell activa-
tion is vital for cellular transformation, and various sig-
naling pathways are triggered by the T-cell receptor that
play key roles in controlling T-cell activation. For ex-
ample, recent findings define MALT1 (mucosa-associ-
ated-lymphoid-tissue lymphoma-translocation gene 1)
as a protein with proteolytic activity that controls T-cell
activation by regulating key molecules in T-cell receptor
(TCR)-induced signaling pathways [15]. Moreover, a
number of studies have shown that in A20 (tumor ne-
crosis factor-α-induced protein 3; TNFAIP3), which is a
nuclear factor kappa B (NF-κB) negative regulator, gen-
etic alterations are frequently found in lymphomas, sug-
gesting that there may be a link between the altered
immune response and leukemogenesis [16-23]. Further-
more, it was shown that TCR stimulation induces the
recruitment of A20 into a CBM complex containing
CARMA1 (caspase-recruitment domain (CARD) contain-
ing membrane-associated guanylate kinase protein 1, also
called CARD11), adaptor protein Bcl-10 (B-cell lymphoma
10), and MALT1 (paracaspase mucosa-associated lymph-
oid tissue lymphoma translocation gene 1), leading to
MALT1-mediated A20 processing. MALT1 cleaves human
A20 after arginine 439 and impairs its NF-κB-inhibitory
function. A20 is a substrate of MALT1, underscoring the
importance of MALT1 proteolytic activity in the ‘fine tun-
ing’ of TCR signaling [24].
A20 is frequently inactivated by deletions and/or mu-
tations in several lymphoma subtypes including B- and
T-cells [16-22]. Recently, bi- and monoallelic A20 dele-
tions in a high proportion of Sezary syndrome patientsand a biallelic A20 deletion in the Sezary syndrome-
derived cell line SeAx were identified. Furthermore, A20
inhibition activates the NF-κB pathway, thereby increas-
ing the proliferation of normal T-cells [17]. Interestingly,
we recently found that there are rare A20 mutations and
polymorphisms in T-ALL [25]. Therefore, it is of interest
to analyze the expression characteristics of A20 and its
regulating factors, including upstream components of
the CBM complex, which includes CARMA1, BCL10,
and MALT1 [24,26-28], which is expected to provide
new insight in the abnormal molecular regulation on T-
cell activation. In this study, we characterized the gene
expression pattern of A20, as well as the gene expression
levels of its upregulating factors CARMA1-BCL10-
MALT1 and its target factor NF-κB in T-ALL.
Methods
Samples
The samples used in this study were derived from 21
newly diagnosed, untreated patients with T-ALL, includ-
ing 17 males and 4 females (4 to 66 years old; median
age: 23.5 years). Sixteen healthy individuals including 10
males and 6 females (17 to 45 years old; median age:
26 years) served as controls. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from heparinized
venous blood by Ficoll-Paque gradient centrifugation.
RNA extraction and cDNA synthesis from PBMCs were
performed according to the manufacturer’s instructions.
All human peripheral blood samples were obtained with
consent from the human subjects. All procedures were
conducted according to the guidelines of the Medical
Ethics Committee of the Health Bureau of Guangdong
Province in China, and ethical approval was obtained
from the Ethics Committee of the Medical School of
Jinan University.
Quantitative real-time RT-PCR (qRT-PCR)
The sequences of the primers used for CARMA1, BCL-10,
MALT1, A20, and NF-κB gene amplification are listed in
Table 1. The expression level of the CARMA1, BCL-10,
MALT1, A20, NF-κB, and β2-microglobulin (β2M) genes
was determined by SYBR Green I real-time PCR as previ-
ously described [4,25,29,30]. The relative amounts of the
genes of interest and the β2M reference gene were mea-
sured in two independent assays. The specific, amplified
PCR products were analyzed by melting curve analysis.
The data are presented as the relative expression of the
genes of interest compared with the internal control gene
as determined by the 2(-ΔCT) method [4,28-30].
Statistical analysis
Two independent-samples Mann-Whitney U tests were
performed to compare the median expression level of
each gene between patients with T-ALL and control
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analyses were used to determine the association be-
tween different genes in different groups. A P <0.05 was
considered statistically significant [29,30].
Results and discussion
Despite significant improvement in our understanding of
T-ALL biology and pathogenesis, knowledge of the on-
cogenic signaling pathways involved in T-ALL remains
limited. Constitutive aberrant activation of the NF-κB
signaling pathway has been detected in various lymphoid
malignancies, and it plays a key role in the development
of these tumors. A20 is a central regulator involved in
the negative feedback regulation of multiple NF-κB-
activating signaling cascades [16,18,31]. Recently, numer-
ous studies showed that A20 is inactivated by deletions
and/or mutations in several lymphoma subtypes, includ-
ing T-cell lymphomas [16-22], and A20 inhibition results
in constitutive NF-κB activation in tumor cells. These data
indicate that A20 inactivation might play a role in malig-
nant T-cells. Bi- and monoallelic A20 deletions in a high
proportion of Sezary syndrome patients were identified
[16]; however, mutations and polymorphisms in A20 rarely
occur in T-ALL [24]. Thus, it is of interest to characterize
the A20 expression pattern in T-ALLs containing an A20
deletion. In this study, we examined the A20 expression
level and found significantly lower A20 expression in
T-ALL patients (median: 4.853) compared with healthy
individuals (median: 8.748; P = 0.017) (Figure 1A).
Thus, we hypothesized that A20 downregulation may
be due to abnormal upstream regulation.
Antigen receptor-mediated NF-κB activation in lym-
phocytes relies on the formation of a large multi-protein
complex containing CARMA1, BCL10, and MALT1
(CBM). MALT1 has proteolytic activity and controls
T-cell activation by regulating NF-κB pathways [14,31],
and it mediates rapid proteolytic cleavage and A20inactivation [23]. Studies in MALT1-deficient mice have
demonstrated an essential role for MALT1 in TCR- and
B-cell receptor-mediated functions [15,28]. The CARMA1-
BCL10-MALT1 pathway is pathologically altered in several
lymphoma subtypes [32], including activated B-cell-like
diffuse large B-cell lymphoma (ABC-DLBCL) [33]. The
CARMA1-BCL10-MALT1 pathway also plays a central
role in TCR signaling that results in T-cell activation and
proliferation [24,26-28,34]. In this study, we attempted to
characterized alterations in the CBM genes in T-ALL. We
examined the expression levels of the CARMA1, BCL10,
and MALT1 genes, and significantly increased expression
levels of CARMA1 (median: 2.916; P = 0.034), BCL10
(median: 0.285; P = 0.033), and MALT1 (median: 1.201;
P = 0.010) were found in T-ALL patients compared with
healthy individuals (median: 1.379, 0.169, and 0.677, re-
spectively) (Figure 1B–D). High expression of the CBM
genes indicates significantly high leukemic T-cell activa-
tion, and high MALT1 expression might mediate A20
downregulation, which was found in the same T-ALL
samples. This finding may also partially explain the
lower expression level of A20 in T-ALL. Because CBM
mediates TCR-induced NF-κB during T-cell activation,
we further analyzed the expression level of NF-κB, and
as expected, NF-κB overexpression (median: 0.714) was
found in T-ALL patients compared with healthy con-
trols (median: 0.335; P = 0.001) (Figure 1E). Overall, we
show that the abnormal expression of CBM and A20 in
T-ALL cells may be related to the abnormal prolifera-
tion of malignant T-cells. This result is consistent with
the finding that A20 is also a putative tumor suppressor
in T-cell malignancies such as Sézary syndrome. In con-
trast, such abnormal expression characteristics may be
considered as biomarkers or target factors in T-ALL.
Overexpression of CARMA1 was reported in angio-
immunoblastic T-cell lymphoma and peripheral T-cell
lymphoma, and it was linked to poor prognosis in a re-
port by Fujiwara et al. [35]. Additionally, in a genome
profile analysis of aggressive adult T-cell leukemia/lymph-
oma, CARMA1 was found to be a potential 7p22 amplifi-
cation target gene in the lymphoma but not acute subtype.
This finding suggests that the acute and lymphoma sub-
types are genomically distinct; thus, they may develop tu-
mors via distinct genetic pathways [7]. However, there are
few reports of CBM molecular aberrations or dysfunction
in T-ALL [4]. In this study, we found that all of the CBM
genes were upregulated, resulting in the downregulation
of A20 and upregulation of NF-κB, which may be a com-
mon characteristic of abnormal proliferation and activa-
tion in T-cell malignancies. Therefore, it is suggested that
such overexpressed genes may be considered potentially
attractive targets for the development of T-ALL therapeu-
tics. It is well known that NF-κB is a target for multiple
myeloma therapy via proteasome inhibitors such as
Figure 1 The expression levels of the (A) A20, (B) CARMA1, (C) BCL10, (D) MALT1, and (E) NF-ΚB genes in healthy individuals and
patients with T-ALL.
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bined therapy for T-cell malignancies [37,38]. Moreover,
two kinds of small molecule inhibitor for MALT1 have
been reported recently. One of them is the phenothiazine
derivative mepazine, which has been shown to have prom-
ising anticancer properties in subtypes of B-cell lymphoma
and could also be used in the treatment of lymphocyte-
mediated autoimmune pathologies such as multiple scler-
osis [39]. The other one is MI-2 which binds directly to
MALT1 and irreversibly suppresses protease function, and
displays selective activity against ABC-DLBCL cell lines
in vitro and xenotransplanted ABC-DLBCL tumors
in vivo. It would be worthy to investigate the anti-T-ALL
effect of such Malt1 inhibitors [40].
We further analyzed associations between the expres-
sion patterns of the CBM, A20, and NF-κB genes. A20 is
generally cleaved by MALT1; thus, the expression level
of MALT1 should be negatively correlated with the A20
and MALT1 expression pattern [41]. We found a nega-
tive correlation between the MALT1 and A20 expression
levels (rs = –0.806, P = <0.0001) in the healthy individual
(Figure 2A) and T-ALL patient groups (rs = –0.450, P =
0.041; Figure 2B) as expected. A negative correlation
was found between the A20 and NF-κB expression levelsFigure 2 Correlation analysis of the expression levels of (A) MALT1 an
(C) A20 and NF-κB in HI, (D) A20 and NF-κB in T-ALL, (E) MALT1 and N
in HI, and (H) CARMA1 and BCL10 in T-ALL.(rs = –0.847, P <0.0001; Figure 2C) in healthy individ-
uals, as expected, while there was no significant correl-
ation between the A20 and NF-κB expression levels in
T-ALL patients (rs = 0.0208, P = 0.929; Figure 2D). More-
over, the negative correlation was lost, and whether this
is due to abnormal CMB regulation remains an open
question. A positive correlation between the MALT1
and NF-κB expression level was also found in healthy
controls (rs = 0.641, P = 0.001; Figure 2E), while there
was no significance in the correlation between genes in
the T-ALL group (rs = 0.193, P = 0.402; Figure 2F). More-
over, we found a significant positive correlation between
the gene expression levels of CARMA1 and BCL10 in
healthy individuals (rs = 0.513, P = 0.042; Figure 2G) and
T-ALL patients (rs = 0.572, P = 0.007; Figure 2H). Overall,
this result indicates that MALT1, A20, and NF-κB lose
their normal expression pattern at the molecular level,
and their manner of regulation in T-ALL may be more
complex. In our previous studies, we found two T-ALL
patients with two malignant Vδ1 and Vδ2 T-cell clones
who had poor outcome, and high expression of the
Notch1 and CARMA-BCL10-MALT1-A20-NF-κB pathway
genes in this biclonal T-ALL patient group compared with
a mono-malignant Vα T-cell clone was found [4]. Basedd A20 in healthy individuals (HI), (B) MALT1 and A20 in T-ALL,
F-κB in HI, (F) MALT1 and NF-κB in T-ALL, (G) CARMA1 and BCL10
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different expression patterns of the CARMA-BCL10-
MALT1-A20-NF-κB pathway genes may be a biomarker
for a genomically-distinct subtype of T-ALL or a prog-
nostic biomarker for T-ALL. Increasing new genetic
markers for ALL have been found to have prognostic
impact [42].
Conclusions
We first characterized the expression pattern of the
CARMA-BCL10-MALT1-A20-NF-κB pathway genes and
found that overexpression of CBM genes in T-ALL may
cause constitutive cleavage and inactivation of A20 to
enhance NF-κB signaling, contributing to the pathogen-
esis of T-ALL. Thus, this pathway may be considered a
potentially attractive target for the development of T-
ALL therapeutics. However, this finding is based only on
results from a limited case analysis and further research
involving more samples is needed to determine repre-
sentative results. Moreover, the change of protein levels
of this pathway are needed to confirm this, especially for
target therapeutic strategy in T-ALL.
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